Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection (NCT02656511) | Clinical Trial Compass
Active — Not RecruitingPhase 4
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
United States74 participantsStarted 2015-12
Plain-language summary
The purpose of this study is to identify and provide immediate antiretroviral therapy to a cohort of HIV-infected individuals with very early HIV infection (estimated date of infection within the last 90 days). The primary aim of the study is to evaluate whether initiation of dolutegravir plus emtricitabine/tenofovir during acute/early HIV infection leads to protection of CD4+ T cells and other immune cells in the peripheral blood and lymphoid tissue from infection.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Willing and able to provide written informed consent
✓. Male or female, age ≥18 years
✓. Acute HIV infection with a negative or indeterminate HIV-1 antibody test and plasma HIV-1 RNA \> 40 cp/ml, OR clinical history consistent with new HIV infection in the last 90 days.
✓. Antiretroviral therapy untreated or recently initiated (within 7 days)
✓. Participant must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
✓. All participants must agree not to participate in a conception process (eg, active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization)..
✓. When participating in sexual activity that could lead to pregnancy, female participants must agree to use a double barrier method of contraception for at least two weeks after discontinuation of study drug.
Exclusion criteria
✕. Known severe kidney disease (CrCl \< 60 ml/min via Cockcroft-Gault method)
✕. Known severe hepatic impairment (Child-Pugh Class C)
✕. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
✕
What they're measuring
1
Safety and tolerability of immediate Dolutegravir plus Emtricitabine/Tenofovir administered to acutely infected HIV patients.
. Participants with anticipated need for Hepatitis C virus (HCV) therapy during study
✕. Concurrent treatment with dofetilide, oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St. John's wort, or metformin
✕. Serious illness requiring systemic treatment and/or hospitalization in the preceding 90 days prior to study enrollment
✕. Concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drugs in the preceding 90 days prior to study enrollment (e.g. IL-2, interferon-alpha, methotrexate, cancer chemotherapy)
✕. Concurrent treatment with investigational drugs, or exposure to any investigational drugs in the preceding 90 days prior to study enrollment